CXCL8 and colorectal carcinoma: In detail, high levels of CXCL8, VEGF and PTX-3 (≥ROC value) identified subgroups of CRC patients [44.4% (28/63); 42.8% (27/63); 15.8% (10/63), respectively] that efficiently detected disease recurrences [47.3% (9/19); 50.0% (9/18); 50.0% (5/5)].